
Sun Pharma forays into Japan with $293 million product buy from Novartis
pharmafile | March 30, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing |Â Â Japan, M&A, MA, Novartis, Sun Pharma, genericsÂ
Shares of Sun Pharma (BOM: 524715), the largest Indian drug maker rose over 2% Wednesday as the company announced the acquisition of 14 brands in Japan from Swiss pharma major Novartis (VTX: NOVN) for $293 million.
Under the terms of the deal, Novartis will continue to distribute these brands, for a certain period, pending transfer of all marketing authorizations to Sun Pharma.
Novartis brands had combined annualized revenues of about $160 million and address medical conditions across several therapeutic areas, the company said in a statement.
Sun Pharma’s managing director, Dilip Shanghvi, says: “Japan is a market of strategic interest for us. This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future.”
The Japanese pharmaceutical market is estimated to be worth $73 billion, accounting for over 7% of the $1 trillion global pharmaceutical market.
Shares in the company were trading up over 2% at 810.50 rupees on the Bombay Stock Exchange Wednesday.
Anjali Shukla
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

First malaria medicine for infants under 4.5kg receives approval
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …






